NASDAQ: $RNA NEJM Publishes Phase 1/2 MARINA Trial Results for Delpacibart Etedesiran in DM1 Treatment Avidity Biosciences, Inc., a company pioneering a new class of RNA therapeutics known as Antibody Oligonucleotide Conjugates (AOCs™), has reached a significant milestone. The final results from the completed Phase 1/2 MARINA® trial investigating delpacibart etedesiran (del-desiran) for the treatment…